Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06735534 · ClinicalTrials.gov registry record · NA
Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System
A NA study of Persistent Atrial Fibrillation, sponsored by Boston Scientific Corporation.
- Recruiting
- Registry status
- NA
- Development phase
- 407
- Enrollment target
- 20
- Study locations
NCT06735534 is a NA study of Persistent Atrial Fibrillation that is actively recruiting participants, run by Boston Scientific Corporation. The registered enrollment target is 407 participants, below the 1,233-participant average among 15 other Persistent Atrial Fibrillation trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT06735534, a NA study of Persistent Atrial Fibrillation, is actively recruiting participants, sponsored by Boston Scientific Corporation.
- RECRUITING
- Registry status
- NA
- Development phase
- 407 participants
- Enrollment target
- 20
- Study locations
Study Summary
The ReMATCH Study is a prospective, single arm, open label, multi-center, study utilizing the FARAPULSE PFA System, including the FARAWAVE and FARAPOINT PFA Catheters.
Conditions Studied
Interventions
- DEVICE FARAPULSE™ Pulsed Field Ablation System
Study Locations (20)
California
- University of Southern California Hospital - Los Angeles
- Stanford University Medical Center - Stanford
Florida
- HCA Florida Mercy Hospital - Miami
- Naples Comprehensive Health - Naples
Georgia
- Emory University Hospital - Atlanta
- Memorial Health University Medical Center - Savannah
Massachusetts
- Massachusetts General Hospital - Boston
- Southcoast Physicians Group - Fall River
Ohio
- Bethesda North Hospital - Cincinnati
- Ohio State University Medical Center - Columbus
Alabama
- Mobile Infirmary Medical Center - Mobile
Arkansas
- Arrhythmia Research Group-Research Facility - Jonesboro
Colorado
- South Denver Cardiology Associates, PC - Littleton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 407 participants |
| Start Date | 2025-06-03 |
| Est. Completion | 2028-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06735534
The ClinicalTrials.gov registry entry for NCT06735534 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 407 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,233-participant average among 15 other Persistent Atrial Fibrillation trials with a reported enrollment target (67% lower). The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Persistent Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which FARAPULSE™ Pulsed Field Ablation System is the first listed.
NCT06735534 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT06735534 about?
NCT06735534 is a clinical study titled "Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System". The ReMATCH Study is a prospective, single arm, open label, multi-center, study utilizing the FARAPULSE PFA System, including the FARAWAVE and FARAPOINT PFA Catheters.
What is the current status of trial NCT06735534?
This trial is currently recruiting. It is a NA study. The enrollment target is 407 participants. The study started on 2025-06-03. Estimated completion is 2028-01.
What conditions does trial NCT06735534 study?
This clinical trial studies the following conditions: Persistent Atrial Fibrillation.
What interventions are being tested in trial NCT06735534?
The interventions under investigation include: FARAPULSE™ Pulsed Field Ablation System (DEVICE).
Who is sponsoring clinical trial NCT06735534?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06735534 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Persistent Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Endocardial Mapping With the CoreMap EP Mapping System
RECRUITING · NA
-
ULTRA-HFIB-Redo: Ultrasound-based Renal Sympathetic Denervation vs Control in Redo Ablation Patients
RECRUITING · NA
-
ARIADNE Clinical Trial
RECRUITING · NA
-
Medtronic Terminate AF Study
RECRUITING · NA
-
Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation
ACTIVE NOT RECRUITING · NA
-
AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.